Skip to main content
SpringerLink
Log in

Risks and Benefits of Low Molecular-Weight Heparin and Target-Specific Oral Anticoagulant Use for Thromboprophylaxis in Medically Ill Patients

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Venous thromboembolism is the third most common cardiovascular disease and a major cause of inpatient mortality as over 50 % of deep vein thrombosis and pulmonary embolism are undetected in medically treated patients. Several agents are approved for thromboprophylaxis, including warfarin, unfractionated heparin, low molecular-weight heparins, fondaparinux, and target-specific oral anticoagulants. The purpose of this literature review is to discuss the increased risk of venous thromboembolism in medically ill patients and the literature surrounding the efficacy and tolerability of low molecular-weight heparins and target-specific oral anticoagulants for this indication. PubMed, MEDLINE, EBSCOhost, and clinicaltrials.gov were used as search engines in the literature review. Search limits included articles containing human subjects, scholarly (peer-reviewed) journals written in English, and publication dates from 2004 to 2014. Animal studies, non-English articles, and publications dated prior to 2004 were excluded. Recurrent venous thromboembolism remains an ongoing problem affecting thousands of people in the non-surgical population annually. With limited data, it is not likely that target-specific oral anticoagulants will soon replace low molecular-weight heparins or even be considered an alternative until efficacy and tolerability have been established. Until further evidence is disclosed, low molecular-weight heparins and fondaparinux (in the absence of renal dysfunction and low body weight) should continue to be utilized as first-line agents for thromboprophylaxis in medically ill patients. The use of apixaban and rivaroxaban is discouraged for thromboprophylaxis in medically ill patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Deitcher SR, Carman TL. Deep venous thrombosis and pulmonary embolism. Curr Treat Opt Cardiovasc Med. 2002;4:223–38.

    Article  Google Scholar 

  2. Bergmann JF, Kher A. Venous thromboembolism in the medically ill patient: a call to action. Int J Clin Pract. 2005;59:555–61.

    Article  PubMed  Google Scholar 

  3. Surgeon General’s Call to Action To Prevent Deep Vein Thrombosis and Pulmonary Embolism. U.S. Department of Health and Human Services (HHS) under the direction of the Office of the Surgeon General and the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Washington, DC; 2008.

  4. Centers for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations—United States, 2007–2009. MMWR Morb Mortal Wkly Rep. 2012;61:401–4.

    Google Scholar 

  5. National Institute for Health and Clinical Excellence. National Clinical Guideline Centre—Acute and Chronic Conditions (UK). Venous thromboembolism: reducing the risk and venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE: London; 2010.

  6. Fanikos J, Piazza G, Zayaruzny M, et al. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost. 2009;102:688–93.

    CAS  PubMed  Google Scholar 

  7. Coumadin® [package insert]. Princeton: Bristol-Myers Squibb Co.; 2011.

  8. Heparin sodium injection [package insert]. New York, NY; Pfizer, Inc.; 2013.

  9. Fragmin® [package insert]. New York: Pfizer, Inc.; 2010.

  10. Lovenox® [package insert]. Bridgewater: Sanofi-Aventis, LLC.; 2013.

  11. Arixtra® [package insert]. Research Triangle Park, NC; GlaxoSmithKline Co.; 2013.

  12. Xarelto® [package insert]. Titusville: Janssen Pharmaceuticals, Inc.; 2014.

  13. Eliquis® [package insert]. Princeton: Pfizer, Inc.; 2014.

  14. Weitz JL. Management of venous thromboembolism: present and future. Circulation. 2004;110:1–2.

    Google Scholar 

  15. Jaffer AK, Amin AN, Brotman DJ, et al. Prevention of venous thromboembolism in the hospitalized medical patient. Cleveland Clin J Med. 2008;75(Suppl 3):S7–16.

    Article  Google Scholar 

  16. Center for Disease Control and Prevention. Deep vein thrombosis (DVT)/pulmonary embolism (PE)—blood clot forming in a vein. Updated 8 June 2012. http://www.cdc.gov/ncbddd/dvt/data.html. Accessed 30 Aug 2014.

  17. Guyatt GH, Akl EA, Crowther M, et al. Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl):7S–47S.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Tapson VF, Decousus H, Pini M, et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132:936–45.

    Article  PubMed  Google Scholar 

  19. Spyropoulos AC, Anderson FA, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140:706–14.

    Article  PubMed  Google Scholar 

  20. Mahan CE, Liu Y, Turpie AG, et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Haemost. 2014;112:692–9.

    Article  PubMed  Google Scholar 

  21. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139:69–79.

    Article  PubMed  Google Scholar 

  22. Squizzato A, Ageno W. A new era for venous thromboembolism prevention in medical inpatients. Thromb Haemost. 2014;112:627–8.

    Article  PubMed  Google Scholar 

  23. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450–7.

    Article  CAS  PubMed  Google Scholar 

  24. Wicki J, Perneger TV, Junod AF, et al. Assessing clinical probability of pulmonary embolism in the emergency ward. Arch Intern Med. 2001;161:92–7.

    Article  CAS  PubMed  Google Scholar 

  25. Nendaz M, Spirk D, Kucher N, et al. Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism. Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland (ESTIMATE). Thromb Haemost. 2014;111:531–8.

    Article  CAS  PubMed  Google Scholar 

  26. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–9.

    Article  CAS  PubMed  Google Scholar 

  27. Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43:1064–83.

    Article  CAS  PubMed  Google Scholar 

  28. Kucher N, Leizorovicz A, Vaitkus PT, et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med. 2005;165:341–5.

    Article  CAS  PubMed  Google Scholar 

  29. Cohen AT, Turpie AG, Leizorovicz A, et al. Thromboprophylaxis with dalteparin in medical patients: which patients benefit? Vasc Med. 2007;12:123–8.

    Article  PubMed  Google Scholar 

  30. Pincus KJ, Hynicka L. Prophylaxis of thromboembolic events in patients with nephrotic syndrome. Ann Pharmacother. 2013;47:725–34.

    Article  PubMed  Google Scholar 

  31. Cook D, Meade M, Guyatt G, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364:1305–14.

    Article  CAS  PubMed  Google Scholar 

  32. Pineo GF, Hull RD. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. Eur J Med Res. 2004;9:215–24.

    CAS  PubMed  Google Scholar 

  33. Bergmann JF, Neuhart E. A multicenter randomized double blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost. 1996;76:529–34.

    CAS  PubMed  Google Scholar 

  34. Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low-molecular weight heparin for prevention of deep vein thrombosis in medical patients. Thromb Res. 1990;59:639–50.

    Article  CAS  PubMed  Google Scholar 

  35. Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis. 1996;26:127–39.

    CAS  PubMed  Google Scholar 

  36. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular weight heparin (enoxaparin). Haemostasis. 1996;26(Suppl 2):49–56.

    CAS  PubMed  Google Scholar 

  37. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614–21.

    Article  CAS  PubMed  Google Scholar 

  38. McGarry LJ, Stokes ME, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs unfractionated heparin in medical inpatients. Thromb J. 2006;4:17.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793–800.

    Article  CAS  PubMed  Google Scholar 

  40. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med. 2004;164:963–8.

    Article  PubMed  Google Scholar 

  41. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8–18.

    Article  PubMed  Google Scholar 

  42. Kakker AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365:2463–72.

    Article  Google Scholar 

  43. Shogbon A, Marshall J. Utilization of low molecular weight heparins in special populations: renal impairment and obesity. ASHP: New Practitioners Forum. 2011.

  44. Kanaan AO, Silva MA, Donovan JL, et al. Meta-analysis of venous thromboembolism prophylaxis in medically ill patients. Clin Ther. 2007;29:2395–405.

    Article  CAS  PubMed  Google Scholar 

  45. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med. 2007;356:2653–5.

    Article  CAS  PubMed  Google Scholar 

  46. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008;99:779–81.

    CAS  PubMed  Google Scholar 

  47. Burch M, Cooper B. Fondaparinux-associated heparin-induced thrombocytopenia. Proc (Bayl Univ Med Cent). 2012;25:13–5.

    PubMed Central  PubMed  Google Scholar 

  48. Cohen AT, Davidson BL, Callus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ. 2006;7537:325–9.

    Article  Google Scholar 

  49. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–23.

    Article  CAS  PubMed  Google Scholar 

  50. US FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy [press release]. http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_the_risk_of_recurrent_dvt_and_pe_following_initial_therapy. Accessed 29 Aug 2014.

  51. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.

    Article  CAS  PubMed  Google Scholar 

  52. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.

    Article  CAS  PubMed  Google Scholar 

  53. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–77.

    Article  CAS  PubMed  Google Scholar 

  54. Crowther M, Kitt M, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT4445, a novel, universal antidote for direct and indirect Factor Xa inhibitors. In: Presented at the International Society on Thrombosis and Haemostasis Congress. Amsterdam; 2013.

  55. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51.

    Article  CAS  PubMed  Google Scholar 

  56. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25:101–61.

    Google Scholar 

  57. Efficacy and safety of low-molecular weight heparin for thromboprophylaxis in acutely ill medical patients. http://clinicaltrials.gov/show/NCT00311753. Accessed 30 Aug 2014.

  58. Evaluation of AVE5026 in the prevention of venous thromboembolism in acutely ill medical patients with restricted mobility. http://clinicaltrials.gov/ct2/show/results/NCT00714597. Accessed 31 Aug 2014.

  59. A study of rivaroxaban (JNJ-39039039) on the venous thromboembolic risk in post-hospital discharge patients (MARINER). https://clinicaltrials.gov/ct2/show/NCT02111564. Accessed 8 Feb 2015.

  60. Acute medically ill VTE prevention with extended duration betrixaban study (The APEX Study). https://clinicaltrials.gov/ct2/show/study/NCT01583218. Accessed 8 Feb 2015.

  61. Pradaxa® [package insert]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015.

  62. Savaysa® [package insert]. Parisippany: Daiichi Sankyo, Co.; 2015.

  63. Betrixaban: FXa inhibitor. http://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/ Accessed 8 Feb 2015.

Download references

Compliance with ethical standards

Drs. Genevieve Hale and Michael Brenner do not have any conflicts of interest or funding to disclose. No internal or external sources of financial assistance were used to assist with the preparation of this manuscript.

Author information

Authors and Affiliations

  1. VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA

    Genevieve Hale & Michael Brenner

Authors
  1. Genevieve Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Brenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Brenner.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hale, G., Brenner, M. Risks and Benefits of Low Molecular-Weight Heparin and Target-Specific Oral Anticoagulant Use for Thromboprophylaxis in Medically Ill Patients. Am J Cardiovasc Drugs 15, 311–322 (2015). https://doi.org/10.1007/s40256-015-0122-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-015-0122-7

Keywords

Search

Navigation